Lorlatinib: A Revolution for ALK-positive Lung Cancer

Developed by Pfizer, lorlatinib (brand name: Lorbrena®) is a third-generation dual-target tyrosine kinase inhibitor targeting ALK and ROS1. It is specially indicated for patients with locally advanced or metastatic ALK-positive non-small cell lung cancer.

Lorlatinib approval for marketing:

• September 21, 2018:  Approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA)
• November 2, 2018:   Granted accelerated approval by the U.S. Food and Drug Administration (FDA)
• March 2019:  Approved by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
• April 2022: Approved by China's National Medical Products Administration (NMPA)
• March 2023 :    Included in China's National Medical Insurance Catalogue 

Prices of Lorlatinib

• Original Lorlatinib in China (Reimbursed by Medical Insurance)

After being included in medical insurance in 2023, the reimbursed price ranges from 5,000 to 6,500 RMB per box.

• Generic Lorlatinib Prices

The price of generic versions is approximately 2,000 to 3,000 RMB per box.

PHOLORLA (Lorlatinib): Pharma 2 Vientiane, Laos

Lorlacare (Lorlatinib): ElementoPharma, Laos

Lorlanib (Lorlatinib): Drug International Limited (DIL), Bangladesh

Lorbrexen (Lorlatinib): Everest Pharmaceuticals, Bangladesh

Lorlatinib

Lorlatinib Starting Materials and Intermediates

RELYBO is committed to providing global customers with high-purity, high-quality Lorlatinib  intermediates with stable supply from kilogram to ton cales, accelerating the innovation and commercialization.